Pokorova et al., 2002 - Google Patents
Antigenic and adjuvant activities of branched aliphatic oligoester (M-DL-LA) microspheres with incorporated bovine rotavirusPokorova et al., 2002
View PDF- Document ID
- 16837104345638862390
- Author
- Pokorova D
- Reschova S
- Franz J
- Hampl J
- Dittrich M
- Publication year
- Publication venue
- Drug Delivery
External Links
Snippet
Branched aliphatic oligoester microspheres (msp) with incorporated rotavirus were used to induce the production of systemic and mucosal antibodies in mice. The msp with a mean diameter of 7.4 μm were prepared by the w/o/w technique. The mice were immunized …
- 230000000694 effects 0 title abstract description 13
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nazarian et al. | A PLGA-encapsulated chimeric protein protects against adherence and toxicity of enterotoxigenic Escherichia coli | |
| Pawar et al. | Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity | |
| Sarti et al. | In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A | |
| Herrmann et al. | Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles | |
| Jain et al. | PEG–PLA–PEG block copolymeric nanoparticles for oral immunization against hepatitis B | |
| Vajdy et al. | Microparticles for intranasal immunization | |
| van der Lubben et al. | Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice | |
| Pawar et al. | Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response | |
| Kim et al. | Oral immunization with Helicobacter pylori‐loaded poly (d, l‐lactide‐co‐glycolide) nanoparticles | |
| Yuan et al. | Induction of mucosal immune responses and protection against enteric viruses: rotavirus infection of gnotobiotic pigs as a model | |
| Kim et al. | Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly (D, L-lactide-co-glycolide) microparticles | |
| US20180071387A1 (en) | Immunomodulatory compositions comprising a polymer matrix and an oil phase | |
| Offit et al. | Enhancement of rotavirus immunogenicity by microencapsulation | |
| Edelman et al. | Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide) | |
| Qiao et al. | Recombinant lactic acid bacteria as promising vectors for mucosal vaccination | |
| US20020009457A1 (en) | Vaccine composition, method of preparing the same, and method of vaccinating vertebrates | |
| Mangal et al. | Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system (s) administered intranasally | |
| CN101163500B (en) | Composition for adjuvant containing poly-gamma-glutamic acid | |
| Kende et al. | Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge | |
| Nayak et al. | Formulation, characterization and evaluation of rotavirus encapsulated PLA and PLGA particles for oral vaccination | |
| AU2008296241B2 (en) | Thermal inactivation of rotavirus | |
| Sturesson et al. | Comparison of poly (acryl starch) and poly (lactide-co-glycolide) microspheres as drug delivery system for a rotavirus vaccine | |
| Kunisawa et al. | Characterization of mucoadhesive microspheres for the induction of mucosal and systemic immune responses | |
| CN1128953A (en) | Hydrogel microencapsulated vaccines | |
| Lee et al. | Efficacy of thiolated eudragit microspheres as an oral vaccine delivery system to induce mucosal immunity against enterotoxigenic Escherichia coli in mice |